Literature DB >> 27125307

The NOTCH1/CD39 axis: a Treg trip-switch for GvHD.

B Del Papa1, A Pierini1,2, P Sportoletti1, S Baldoni3, D Cecchini1, E Rosati4, E Dorillo1, P Aureli1, T Zei1, R Iacucci Ostini1, L Ruggeri1, A Carotti1, A Velardi1, R Negrin2, M F Martelli1, F Falzetti1, M Di Ianni3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27125307     DOI： 10.1038/leu.2016.87

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  21 in total

1.  Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Stephan Lang; Theresa L Whiteside
Journal:  J Immunol Methods       Date:  2011-04-13       Impact factor: 2.303

2.  Polyoxometalates--a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitors.

Authors:  Christa E Müller; Jamshed Iqbal; Younis Baqi; Herbert Zimmermann; Anita Röllich; Holger Stephan
Journal:  Bioorg Med Chem Lett       Date:  2006-09-25       Impact factor: 2.823

3.  Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.

Authors:  Antonio Pierini; Lucrezia Colonna; Maite Alvarez; Dominik Schneidawind; Hidekazu Nishikii; Jeanette Baker; Yuqiong Pan; Mareike Florek; Byung-Su Kim; Robert S Negrin
Journal:  J Immunol       Date:  2015-05-20       Impact factor: 5.422

4.  Mitochondria are gate-keepers of T cell function by producing the ATP that drives purinergic signaling.

Authors:  Carola Ledderose; Yi Bao; Markus Lidicky; Johannes Zipperle; Linglin Li; Katharina Strasser; Nathan I Shapiro; Wolfgang G Junger
Journal:  J Biol Chem       Date:  2014-07-28       Impact factor: 5.157

5.  CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.

Authors:  Xiaofeng Sun; Yan Wu; Wenda Gao; Keiichi Enjyoji; Eva Csizmadia; Christa E Müller; Takashi Murakami; Simon C Robson
Journal:  Gastroenterology       Date:  2010-06-25       Impact factor: 22.682

6.  HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse.

Authors:  Massimo F Martelli; Mauro Di Ianni; Loredana Ruggeri; Franca Falzetti; Alessandra Carotti; Adelmo Terenzi; Antonio Pierini; Maria Speranza Massei; Lucia Amico; Elena Urbani; Beatrice Del Papa; Tiziana Zei; Roberta Iacucci Ostini; Debora Cecchini; Rita Tognellini; Yair Reisner; Franco Aversa; Brunangelo Falini; Andrea Velardi
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

7.  Blockade of individual Notch ligands and receptors controls graft-versus-host disease.

Authors:  Ivy T Tran; Ashley R Sandy; Alexis J Carulli; Christen Ebens; Jooho Chung; Gloria T Shan; Vedran Radojcic; Ann Friedman; Thomas Gridley; Amy Shelton; Pavan Reddy; Linda C Samuelson; Minhong Yan; Christian W Siebel; Ivan Maillard
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 8.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  CD39/adenosine pathway is involved in AIDS progression.

Authors:  Maria Nikolova; Matthieu Carriere; Mohammad-Ali Jenabian; Sophie Limou; Mehwish Younas; Ayrin Kök; Sophie Huë; Nabila Seddiki; Anne Hulin; Olivier Delaneau; Hanneke Schuitemaker; Joshua T Herbeck; James I Mullins; Maria Muhtarova; Armand Bensussan; Jean-François Zagury; Jean-Daniel Lelievre; Yves Lévy
Journal:  PLoS Pathog       Date:  2011-07-07       Impact factor: 6.823

Review 10.  Graft versus host disease: New insights into A2A receptor agonist therapy.

Authors:  Karlie R Jones; Elizabeth M Kang
Journal:  Comput Struct Biotechnol J       Date:  2014-12-14       Impact factor: 7.271
View more
  7 in total

Review 1.  Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?

Authors:  F Lussana; M Di Ianni; A Rambaldi
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

2.  Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.

Authors:  Mauro Di Ianni; Paola Olioso; Raffaella Giancola; Stella Santarone; Annalisa Natale; Gabriele Papalinetti; Ida Villanova; Stefano Baldoni; Ambra Di Tommaso; Tiziana Bonfini; Patrizia Accorsi; Paolo Di Bartolomeo
Journal:  Int J Hematol       Date:  2017-07-18       Impact factor: 2.490

3.  Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease.

Authors:  Mette D Hazenberg; Nienke J E Haverkate; Yannouck F van Lier; Hergen Spits; Lisette Krabbendam; Willem A Bemelman; Christianne J Buskens; Bianca Blom; Medya M Shikhagaie
Journal:  Blood Adv       Date:  2019-11-26

Review 4.  The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease.

Authors:  Petya Apostolova; Robert Zeiser
Journal:  Front Immunol       Date:  2016-10-21       Impact factor: 7.561

Review 5.  Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.

Authors:  Govindarajan Thangavelu; Bruce R Blazar
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

Review 6.  Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.

Authors:  Tomomi Toubai; Nathan D Mathewson; John Magenau; Pavan Reddy
Journal:  Front Immunol       Date:  2016-11-29       Impact factor: 7.561

Review 7.  NOTCH and Graft-Versus-Host Disease.

Authors:  Mauro Di Ianni; Beatrice Del Papa; Stefano Baldoni; Ambra Di Tommaso; Bianca Fabi; Emanuela Rosati; Annalisa Natale; Stella Santarone; Paola Olioso; Gabriele Papalinetti; Raffaella Giancola; Patrizia Accorsi; Paolo Di Bartolomeo; Paolo Sportoletti; Franca Falzetti
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.